Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
Follow LTGO by emailGet an email when LTGO pushes back a promised milestone, files for a stock offering or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about LTGO, unsubscribe in one click. Privacy
📣 What LTGO Says Is Next
second half of 2027 · “Expect to report topline results from the Phase 2 clinical trial in the second half of 2027.”
Company press release, Sep 3, 2026 · SEC filing
second half of 2027 · “Expect to report topline results from the Phase 3 bunionectomy and open-label safety clinical trials in the second half of 2027.”
Company press release, Sep 3, 2026 · SEC filing
second half of 2026 · “Plan to initiate a randomized, double-blind, placebo-controlled Phase 3 clinical trial in patients with moderate-to-severe acute pain after bunionectomy surgery as well as a single-arm, open-label Phase 3 safety trial in the second half of 2026.”
Company press release, Sep 3, 2026 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
Get the full LTGO picture
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for LTGO and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.